Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Seborrheic keratosis (SK) is a common, benign skin tumor characterized by the clonal proliferation of epidermal keratinocytes [1]. These lesions typically present as well-demarcated, "stuck-on" pigmented plaques and are composed of a variety of cellular components, including basaloid cells, squamous cells, and melanocytes [2]. While not a single molecular target, SK lesions are often driven by somatic mutations in the Fibroblast Growth Factor Receptor 3 (FGFR3) and the PIK3CA gene [3]. Pharmacological treatment, such as high-concentration topical hydrogen peroxide (40%), targets the lesion's general cellular structure through non-specific oxidative damage, leading to localized tissue necrosis and sloughing [4]. Because "general cellular components" refers to the entire pathological tissue rather than a specific protein or pathway, it is classified as a disease state or lesion rather than a canonical therapeutic target [5]. Understanding the cellular makeup of these lesions is crucial for distinguishing them from malignant mimics like melanoma or basal cell carcinoma [1]. Sources: [1] StatPearls, Seborrheic Keratosis; [2] PubMed, Pathogenesis of seborrheic keratosis; [3] Journal of Investigative Dermatology, FGFR3 and PIK3CA mutations in SK; [4] FDA, Eskata Prescribing Information; [5] American Academy of Dermatology, Seborrheic Keratosis Overview.
Induction of localized oxidative damage and tissue necrosis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General cellular components in seborrheic keratosis lesions.